MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
18 Jun 2020
479
Molecular Biomedicine Issued by Springer Nature Starts Accepting Paper Submissions with Publication Fee Waived for the First Two Years
SCIMEA

Molecular Biomedicine is a full English biomedical journal published by the world-renowned scientific journal publishing company Springer Nature and Sichuan International Medical Exchange & Promotion Association (https://www.springer.com/journal/43556, click "Show all"). Molecular Biomedicine is a peer-reviewed online open access journal that promptly publishes basic research and clinical research in biomedicine based on molecular perspective, with focus on the latest research on occurrence mechanism, prevention, diagnosis and treatment of human diseases. It strives to become a high-quality SCI academic journal with international influence in biomedicine.

image.png

The editor-in-chiefs of Molecular Biomedicine include Professor Arnold JM Driessen (member of the Royal Netherlands Academy of Arts and Sciences) from University of Groningen and Professor Wei Yuquan (member of the Chinese Academy of Sciences) from the State Key Laboratory of Biotherapy in West China Hospital of Sichuan University. Famous scientists from different countries make up the team of deputy editor-in-chiefs and editorial members. The types of papers published in this journal include Research Articles, Reviews, Letters, and Research Highlights. It adopts a "quick passage" model for original achievements to help authors get their papers published quickly with a minimum time of only one week for review and acceptance. From 2020 to 2022, the article processing charge (APC) will be waived.

The publication of the journal includes but not limited to the following topics:

 


• Epigenetics, genomics and proteomics

• Gene editing

• RNA biology

• Signal transduction

• Structural biology

• Early diagnosis of diseases and biomarkers

• Gene therapy, cell therapy and immunotherapy

• Small molecule targeted therapy

• Molecular imaging

• Artificial intelligence in medicine

• Regenerative medicine

 

Molecular Biomedicine 

Molecular Biomedicine sincerely opens its arm to scientific researchers, doctors, and graduate students in biomedicine for paper submission.

 

Editors in Brief

 image.png

Arnold J M Driessen 教授

Professor Arnold J M Driessen

Arnold JM Driessen, professor of molecular microbiology at the University of Groningen. former director of the Institute of Biomolecular Science and Biotechnology at the University of Groningen, and one of the founders of the Groningen Center for Synthetic Biology and the Center for Sustainable Antibacterial (CESAM). He won the Kluyver Award of the Dutch Microbiological Society and the FEBS Anniversary Award of the Biochemical Society. Professor Arnold J.M. Driessen is a member of the Royal Netherlands Academy of Arts and Sciences, and has served as chairman of the Dutch Society of Biochemistry and Molecular Biology. He has authored more than 460 research papers, wrote and edited two books, and (co-)invented 11 patents. He is an outstanding scientist whose papers are highly cited (over 32,000 times) with an academic h-index of 97.

 

 image.png

Professor Wei Yuquan

Biotherapy West China Hospital, Sichuan University

State Key Laboratory, Clinical Oncology Center

Wei Yuquan, professor and doctoral tutor. He was elected academician of the Chinese Academy of Sciences in 2003. Former vice president of Sichuan University. Director of the Clinical Oncology Center and Director of the State Key Laboratory of Biotherapy in West China Hospital. Chairman of the China Medicinal Biotechnology Association. Responsible person of National Biotherapy Collaborative Innovation Center. Responsible person of the National Comprehensive New Drug Research and Development Technology Platform. Professor Wei Yuquan is mainly engaged in basic research, key technology development, product development and treatment of tumor biotherapy. He has published more than 300 SCI papers in various international magazines and served as editor-in-chief of Signal Transduction and Targeted Therapy, deputy editor-in-chief of Human Gene Therapy, and member of the editorial board of several international journals.


On the Way | Visiting Member Enterprise Jinrui Foundation
"Equal Emphasis on Theory and Application, Progress Based on Status Quo" – Critical Care Medical Team Highlights at the Chinese Critical Care Congress 2019
Secrets of Cosmetic Plastic Surgery, Something You May Be Curious about!
2nd Notice on 2019 China-Japan Advanced Medical and New Drug R&D Summit Forum & Achievements Transformation Conference
Interview | Daisaku Sato: Mutual Learning Essential to Drug Administrations for Constant Improvement
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1